Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00731549 · ClinicalTrials.gov registry record · Phase 3

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

A Phase 3 study of Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.

Completed
Registry status
Phase 3
Development phase
1,081
Enrollment target
20
Study locations

NCT00731549 is a Phase 3 study of Schizophrenia that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 1,081 participants, above the 216-participant average among 315 other Schizophrenia trials with a reported enrollment target (400% higher). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00731549, a Phase 3 study of Schizophrenia, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.

COMPLETED
Registry status
Phase 3
Development phase
1,081 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Aripiprazole IM Depot

Study Locations (20)

California

  • - Anaheim
  • - Cerritos
  • - Chino
  • - Escondido
  • - Garden Grove
  • - Glendale
  • - Glendale
  • - Imperial
  • - La Habra
  • - Los Angeles
  • - National City
  • - Oceanside
  • - Orange
  • - Pasadena
  • - Pico Rivera
  • - San Bernardino
  • - San Diego
  • - San Diego
  • Study Site - San Diego

Arizona

  • - Chandler

Trial Details

FieldValue
Enrollment Target 1,081 participants
Start Date 2008-12
Est. Completion 2013-11
Phase Phase 3

Sponsor

Otsuka Pharmaceutical Development & Commercialization

221 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00731549

The ClinicalTrials.gov registry entry for NCT00731549 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,081 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 216-participant average among 315 other Schizophrenia trials with a reported enrollment target (400% higher). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole IM Depot is the first listed.

NCT00731549 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00731549 about?

NCT00731549 is a clinical study titled "Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia". To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.

What is the current status of trial NCT00731549?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,081 participants. The study started on 2008-12. Estimated completion is 2013-11.

What conditions does trial NCT00731549 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00731549?

The interventions under investigation include: Aripiprazole IM Depot (DRUG).

Who is sponsoring clinical trial NCT00731549?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00731549 being conducted?

This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.